PROM1 and chronic myelogenous leukemia, BCR-ABL1 positive: Three weeks of in vivo treatment with nilotinib reduced the absolute number of CML-derived CD45+ leukocytes (Figure S5F) and engrafted CD45+CD34+CD38−and CD45+CD34+CD133+ human cells within the BM (Figs. 5d-e), but the proportion of CML-derived leukocytes in spleen was unaffected (Figure S5G).